Reata pharmaceuticals, inc. (RETA)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating activities
Net loss

-48,939

-186,942

-39,694

-34,380

-29,154

-25,583

-30,834

-28,211

4,082

-16,678

-12,304

-11,591

-7,098

-4,136

-897

-936

-258

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

278

273

258

231

170

120

105

105

101

101

97

109

130

145

170

179

188

Amortization of debt issuance costs and implied interest

489

357

339

339

339

339

339

151

59

-

-

-

-

-

-

-

-

Stock-based compensation expense

19,307

12,291

5,380

4,483

4,227

2,767

2,746

2,552

2,485

1,800

1,545

1,582

1,603

916

716

446

289

Changes in operating assets and liabilities:
Income tax receivable

22,218

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Amounts earned or due from collaboration agreements

-

-

-

-

-

-

-

4,131

25,307

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

198

-1,430

-1,313

3,279

-67

-150

335

795

174

83

-23

228

490

-1,681

842

1,575

482

Other assets

-1,007

-390

-12

-2

-6

-6

-1

260

-273

-250

0

0

769

-

-

-

-

Accounts payable

10,668

-1,674

-752

834

-522

-978

2,887

1,111

-1,065

-354

-195

2,075

-3,289

2,534

-76

826

-2,985

Accrued direct research, other current, and long-term liabilities

-1,976

533

1,640

5,941

3,861

-6,419

2,561

5,639

2,636

-317

3,822

3,384

84

211

427

1,231

1,211

Payable to collaborators

1,578

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Federal income tax receivable/payable

-

-

-

-

-

-

-

-

-

-

-

-

-

0

17,170

-462

15,218

Deferred revenue

-1,169

-192,895

-7,898

-7,813

-7,726

-7,899

-3,766

-2,575

-7,111

-9,509

-12,501

-12,364

-12,229

-12,500

-12,501

-12,365

-12,364

Net cash used in operating activities

-41,173

-149,375

-40,335

-32,709

-28,732

-37,497

3,142

-25,407

-24,021

-24,733

-19,031

-17,434

-22,058

-11,136

3,717

-12,657

817

Purchases of property and equipment

85

253

328

932

1,160

309

102

117

151

136

151

23

34

59

114

151

16

Net cash used in investing activities

-85

-253

-328

-932

-1,160

-309

-102

-117

-151

-135

-151

-23

-34

-58

-114

-151

-16

Payments on deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

76

209

1,411

911

Proceeds from long-term debt

-

-

-

-

-

-

-

-

-

0

0

0

20,000

-

-

-

-

Payments on deferred issuance costs

-

-

-

-

-

1

49

2,237

3

273

0

91

160

-

-

-

-

Exercise of options

1,422

6,952

363

1,034

5,051

381

672

500

332

289

127

3

241

-

-

-

-

Other shareholder transactions

0

0

0

0

107

-

-

-

-

-

-

-

-

-

-

-

-

Payment of capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

45

0

0

0

45

Net cash provided by financing activities

1,422

573,803

363

1,034

5,158

411

233,469

58,263

329

48

108,606

-43

20,036

266

-308

63,320

-956

Net decrease in cash and cash equivalents

-39,836

424,175

-40,300

-32,607

-24,734

-37,395

236,509

32,739

-23,843

-24,820

89,424

-17,500

-2,056

-10,928

3,295

50,512

-155

Supplemental disclosures
Cash paid for interest

3,174

1,981

2,073

2,101

2,052

2,026

1,361

909

445

437

362

360

5

-

-

-

-

Unpaid debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

87

-

-

-

-

Accrued deferred offering cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42

-581

887

Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations

0

806

-719

-655

9,636

-

-

-

-

-

-

-

-

-

-

-

-

Income taxes paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

18

Purchases of equipment in accounts payable, accrued direct research, other current, and long-term liabilities

1,398

157

-25

-580

750

461

-10

-33

74

-

-

-

-

-

-

-

24